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Meropenem versus imipenem/cilastatin in intra-abdominal infections
requiring surgery
S. J. Geroulanos* and the Meropenem Study Grouptt
Department of Surgery, University Hospital, Zurich, Switzerland
In a multicentre, open, randomised study, the efficacy and tolerability of intravenous
meropenem (1 g every 8 h, infusion or bolus) was compared with that of intravenous
imipenem/cilastatin (1 g every 8 h, infusion) in 232 hospitalised patients with moderate
to severe intra-abdominal infections.
At the end of therapy, a satisfactory clinical response (cure or improvement) was
seen in 79/82 (96%) evaluable meropenem patients and 83/88 (94%) imipenem/
cilastatin patients; this was still seen at follow-up (57/63; 90% and 58/66; 88%,
respectively). A satisfactory bacteriological response (elimination or presumed
elimination) was seen in 69/82 (84%) meropenem patients and 71/88 (81%)
imipenem/cilastatin patients at the end of therapy and in 52/62 (84%) and 55/70 (79%),
respectively, at follow-up. There was a high level of clinical cure or improvement (95%
for both treatment groups) in the 120 patients (60 in each group) who had
polymicrobial infections.
A similar incidence of adverse events was seen in each group: 45/116 patients
in the meropenem group (72 events) and 42/116 patients in the imipenem/cilastatin
group (65 events); the adverse event profiles were also similar, with injection site
inflammation and elevated transaminases the most frequent in both groups. The results
of this study indicate that monotherapy with meropenem was as effective and as well
tolerated as the combination of imipenem/cilastatin in the treatment of moderate to
severe intra-abdominal infections.
Introduction
In patients with intra-abdominal infections, the serious consequences of delaying
treatment necessitates the initiation of empirical therapy with antibiotics chosen to reflect
the likely causative organisms. The vast majority of cases also require surgery. Cultures
have demonstrated the polymicrobial nature of many intra-abdominal infections and the
presence of both aerobic and anaerobic organisms in almost half of these infections
requires that antimicrobial regimens have a broad spectrum of activity (Hackford, 1990).
Traditionally, antimicrobial therapy consists of combinations of antibiotics to achieve
sufficient cover. Metronidazole or clindamycin together with a /Mactam antibiotic (e.g.
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cefotaxime) and/or an aminoglycoside are commonly used in such combinations
(Hackford, 1990).
Carbapenems are a new class of /J-lactam antimicrobial with a very broad spectrum
of activity. The only commercially available carbapenem is a formulation of imipenem
in combination with the dehydropeptidase-I (DHP-I) inhibitor, cilastatin given to block
extensive renal metabolism and prevent nephrotoxicity (Benfield & Chrisp, 1992).
Imipenem/cilastatin has high in-vitro activity against the Bacteroidesfragilis group and
most other anaerobic organisms, is active against enterococci, Staphylococcus aureus and
aerobic Gram-negative bacilli (Wilson & Mosimann, 1992), and has been used
successfully in intra-abdominal infections (Christen, Buchmann & Geroulanos, 1987;
Norwegian Study Group, 1987; Geroulanos et al., 1990; Poenaru, De Santis & Christou,
1990; Solomkin et al., 1990; Eckhauser et al., 1992; Eklund el al., 1993).
Potential problems with imipenem/cilastatin include an association with seizures
(usually in patients with pre-existing renal impairment and/or central nervous system
disorders (Guess el al., 1990) and nausea and/or vomiting which may limit toler-
ability and necessitate a slower infusion rate(Calandrae/a/., 19886; Buckley et al., 1992).
Meropenem is a new carbapenem with high in-vitro activity against a wide range of
organisms, both Gram-positive and Gram-negative, including Pseudomonas aeruginosa
and anaerobes. Meropenem also has activity against several subpopulations of bacteria
which are resistant to other antimicrobials, such as tobramycin, ciprofloxacin, norfloxacin
and ceftazidime (Edwards, 1991); and it has a similar but potentially wider spectrum of
activity than imipenem (Bauernfeind, Jungwirth & Scheighart, 1989; Cornaglia el al.,
1992; Morandotti et al., 1992).
The aim of the present study was to compare the clinical and bacteriological efficacy
and safety of empirical monotherapy with intravenous meropenem with the intravenous
combination imipenem/cilastatin in hospitalised patients with intra-abdominal
infections. The pharmacokinetic properties of meropenem and imipenem administered
as imipenem/cilastatin are comparable, following single and multiple dose administration
(Nilsson-Ehle et al., 1991; Drusano, Yuen & Standiford, 1992) and, therefore, the same
dosing regimen (1 g every 8 h) was employed for both antibiotics.
Methods
Study design
This study was conducted at 12 centres in six European countries as a randomised, open,
parallel group comparison of meropenem and imipenem/cilastatin in the surgical
management of intra-abdominal infections.
Patients were included in the study if they were ^ 18 years old and hospitalized with
evidence of a systemic inflammatory response (such as pyrexia, elevated white cell count,
hypotension, increased heart and respiratory rates, altered mental status) and physical
signs consistent with abdominal infection (which included abdominal tenderness,
presence of localised or diffuse abdominal wall rigidity, abdominal mass, or ileus). The
diagnosis was confirmed at operation by the presence of pus, inflammation, intestinal
perforation, abscess or other signs of infection.
Exclusion criteria included: pregnancy or breastfeeding; antibiotic treatment within the
three days before study entry (unless the organism was shown to be resistant or still
present); hypersensitivity to any /}-lactam antibiotics; hepatic failure or hepatic coma;
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neutropenia; and endocarditis. Patients were also excluded if they had a history of central
nervous system (CNS) disease (e.g. seizures, epilepsy, brain disorders or confusional
states).
Reasons for withdrawal from the study included: the occurrence of a serious or
unexpected adverse event; pre-treatment pathogens shown to be resistant to allocated
treatment; any two doses missed within the first 48 h, or two consecutive doses missed
during treatment; deterioration of the patient's condition due to infection; or no
pathogens isolated from pre-treatment cultures.
The study was carried out in accordance with the Declaration of Helsinki (revised
Venice 1983) and all patients gave written or oral consent; local Ethics Committee
approval was obtained from all study centres.
Dosage
Patients were randomised to receive either meropenem or imipenem/cilastatin, each
of which was given iv at a dosage of 1 g every 8 h; meropenem was given either as a
bolus injection (over not less than 5 min) or infused over 20 to 30 min and
imipenem/cilastatin was infused over 30 to 60 min to avoid the nausea and vomiting
associated with more rapid administration (Wang et al., 1985; Norrby et al., 1987). In
each group, a single dose of antibiotic was allowed before surgery. Since both meropenem
and imipenem/cilastatin are chiefly eliminated renally, reductions in dose and/or
frequency of both study drugs were made according to the degree of renal impairment
in both treatment groups.
The recommended duration of therapy was five to 10 days (maximum 28 days)
unless a successful response was reported between 2 and 5 days; no other concurrent
antibiotics were allowed, and concomitant medications and/or interventions were
recorded.
Evaluations
Clinical examinations were performed pre-therapy (within three days before the start of
treatment), daily from Day 2 until the end of therapy, and at 2-4 weeks post-therapy
(follow-up). Patients were evaluated for clinical efficacy as follows:
(a) Cured: complete resolution of local and systemic signs and symptoms of infection
at the end of the treatment period without the addition of other antibiotics or recurrence
of symptoms; (b) Improved: significant improvement in local symptoms and systemic signs
without complete resolution of infection but allowing study treatment to be stopped; (c)
Unchanged/worse: no improvement or deterioration of signs or symptoms; (d)
Unevaluable: any patient receiving less than 48 h treatment; misdiagnosis; any patient
receiving concurrent antibiotics; or major protocol violations; (e) Relapse: infection
cleared at the end of therapy, followed by local or general signs of recurrent infection at
follow-up.
The overall clinical response was assessed at the end of therapy and at follow-up.
Cured and improved were considered satisfactory responses, whereas unchanged/worse
and relapse were considered as unsatisfactory responses. Patients were considered
evaluable if they were both clinically evaluable and had at least one micro-organism
that was sensitive to both of the study drugs isolated from the intra-abdominal site
pre-treatment.
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Appropriate specimens from the infected abdominal site, such as peritoneal fluid,
abscess fluid or pus, and blood cultures were obtained for bacteriological culture not more
than three days pre-treatment or after one dose of antibiotic during surgery and repeated
(if indicated), during treatment, immediately post-treatment, and at 2^4 weeks
post-treatment where possible. Bacteriological response at end of treatment and
follow-up was categorised as: (a) Success: all causative pathogens eradicated;
(b) Presumed success: no further culture available due to clinical improvement; (c) Partial
success: one or more, but not all of the organisms of a polymicrobial infection eradicated,
associated with clinical improvement or cure; (d) Failure: persistence of causative
pathogen; (e) Presumed failure: not confirmed by culture but associated with no clinical
improvement in condition; (f) Partial failure: one or more, but not all of the organisms
of a polymicrobial infection eradicated and associated with clinical failure; (g)
Superinfection: a new pathogen arising during or at end of therapy, requiring antibiotic
or surgical treatment; (h) Unevaluable: no pre-treatment pathogens isolated, no culture
obtained, all pathogens resistant to the study drug, concomitant antibiotics given; (i)
Relapse: initial eradication of pathogens at end of treatment followed by return of the
causative pathogen at follow-up assessment requiring antibiotic or surgical treatment.
Biochemical and haematological monitoring and urinalysis were performed up to 3
days pre-treatment, between days 2 and 4, at least once weekly during treatment and at
the end of treatment. If a clinically significant abnormal result was obtained, tests were
repeated until the parameter returned to normal. Adverse events and local tolerance were
recorded daily. After isolation and identification of pathogens to genus and species level,
susceptibility testing was performed according to the standard accepted disc sensitivity
criteria and measurements of minimum inhibitory concentrations (MICs) were made.
Resistance to meropenem was defined as MIC >8mg/L or zone size of ^10 mm;
corresponding values for imipenem/cilastatin (according to NCCLS criteria) were
> 16 mg/L or < 13 mm, respectively.
Statistical methods
A #-squared test (not continuity corrected) was used to compare the numbers of patients
in each group showing a satisfactory response for the two primary efficacy endpoints
(clinical response in bacteriologically evaluable patients; bacteriological response).
An intention-to-treat analysis was performed on the clinical response data for all patients.
A 95% confidence interval (CI) for the difference in proportions was calculated using a
normal approximation to the binomial (not continuity corrected). Formal statistical
analyses were not performed either on patients returning for a follow-up assessment, or
on safety variables.
Results
Demographics
Of the 232 patients who were recruited, 116 patients received meropenem and 116 patients
received imipenem/cilastatin.
The groups were comparable in terms of demographic characteristics at baseline for
all patients recruited and for those patients that were both clinically and bacteriologically
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evaluable (Table I). On entry to the study, the majority of patients were judged by the
investigator to be in a good to fair condition (78% of meropenem patients and 76% of
imipenem/cilastatin patients), the remainder being considered either in poor clinical
condition or critically ill. All patients received their treatment via a peripheral or central
vein.
The majority of patients had not received any prior antibiotic therapy (78% in the
meropenem, 79% imipenem/cilastatin). The remaining patients in each group had
received antibiotics within 3 days before study entry but their infection was not controlled,
nor a resistant organism isolated.
Approximately two thirds of patients had concurrent abnormalities, mainly
gastrointestinal/hepatobiliary disorders (34 meropenem, 37 imipenem/cilastatin),
cardiovascular disorders (32 meropenem, 26 imipenem/cilastatin) and neoplasms
(14 meropenem, 10 imipenem/cilastatin). The commonest intestinal/hepatobiliary
disorders were cholelithiasis (9 meropenem, 11 imipenem/cilastatin), inflammatory bowel
disease (5 meropenem, 4 imipenem/cilastatin) and diverticulitis (6 meropenem, 4
imipenem/cilastatin). Colorectal neoplasms were the most common neoplasms reported
(7 in each treatment group). The two treatment groups were well matched for underlying
concurrent abnormalities.
Patient numbers
Of the 232 patients recruited to the study, 170 were both clinically and bacteriologically
evaluable (82 meropenem; 88 imipenem/cilastatin). Sixty-two patients were excluded
from the analysis of efficacy (Table II). Eight meropenem patients and five imipenem/
cilastatin patients were judged protocol deviators (e.g. less than 48 h treatment,
resistant pathogens or misdiagnosis) and 49 patients (26 meropenem, 23 imipenem/
cilastatin) were bacteriologically unevaluable, because no organisms were cultured from
pre-treatment samples, or no cultures were obtained. All patients were evaluated for
safety.
Table I. Summary of demographic characteristics
Sex
male
female
Age (years)
mean
range
Race
Caucasian
oriental
other
Mean weight (kg)
males
females
Meropenem
All
patients
( n = 116)
71
45
55
18-92
113
2
1
751
60-8
Evaluable
patients
(n = 82)
50
32
57
18-92
81
0
1
75-2
61-5
Imipenem/cilastatin
All
patients
(n= 116)
67
49
54
18-88
110
5
1
70-3
64-6
Evaluable
patients
(n = 88)
54
34
55
18-88
83
5
0
701
62 8
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Table II. Reason for exclusion from clinical and bacteriological assessments
Reason
Misdiagnosis
Previous tnal entry
Randomisation error
Pre-therapy pathogens resistant
Less than 48 h treatment
Surgery after 3 doses of study drug
No pre-therapy pathogens isolated
Total
Meropenem
0
0
3
2
2
1
26
34
Imipenem/cilastatin
1
1
1
0
2
0
23
28
Infection types
Most of the 170 evaluable patients presented with community-acquired abdominal
infections; 20 patients in the meropenem group and 11 in the imipenem/cilastatin group
had hospital-acquired infections, chiefly as a result of previous surgery. Nineteen
meropenem patients and 11 imipenem/cilastatin patients had undergone surgery in the
two months before the study.
The infections were graded by the investigators as moderate in severity in 66%
of meropenem patients and 67% of imipenem/cilastatin treated patients, severe in
26% and 25% respectively, and mild in the remainder.
The intra-abdominal infections were of various aetiologies which are summarised in
Table III. The intra-abdominal infections were described in relation to the anatomical
site of origin, including the following organ systems; stomach/duodenum, biliary tree
(including gallbladder and hepatic ducts), small bowel, appendix, colon, liver, and
pancreas (peripancreatic abscesses). They were also categorised, on the basis of operative
findings, as abscess and/or peritonitis. The two treatment groups were comparable in
terms of their underlying pathology, although more patients in the imipenem/cilastatin
group had diffuse peritonitis than in the meropenem group. However more patients
in the meropenem group presented with infections following previous elective/
emergency surgery in the previous two months; such infections are often more difficult
to treat.
Patients in the two treatment groups received similar concomitant adjunctive
interventions. Eighty-six percent of meropenem patients had wound drains com-
pared with 88% in the comparator group; 28% of meropenem patients received
ventilatory support compared with 30% of imipenem/cilastatin patients; 35% and 36%
respectively received parenteral nutrition and 58% of patients in the meropenem
group had indwelling urinary catheters compared with 51% in the imipenem/cilastatin
group.
The most common organisms isolated at the time of surgery were streptococcus viridans
(Streptococcus milleri being the most predominant), enterococci, Escherichia coli and
B.fragilis group (B.fragilis sp. being the commonest) (Table VI). Sixty patients in each
treatment group had polymicrobial intra-abdominal infections.
Three patients in the meropenem group and six in the imipenem/cilastatin group were
classified as septicaemic (i.e. had both clinical signs of septicaemia and positive blood
cultures).
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Efficacy
The mean duration of therapy was 7-8 days in the meropenem group and 8-3 days in the
imipenem/cilastatin group.
At the end of therapy, a satisfactory clinical response (cure or improvement) was seen
in 79/82 (96%) meropenem patients and 83/88 (94%) imipenem/cilastatin patients
(Figure 1). The between-group difference (202%) was not statistically significant
(P = 0-534, 95% CI - 4 - 3 % , 8-3%). Of those patients that returned for follow-up
assessment, 57/63 (90%) meropenem patients and 58/66 (88%) of imipenem/cilastatin
patients had a satisfactory response. The clinical response at the end of treatment by site
of infection is shown in Table IV. The intention-to-treat analysis gave essentially the same
result indicating no bias due to exclusion of patients.
Characteristics of the patients whose intra-abdominal infections were unchanged/
worse following study treatment are shown in Table V. In the meropenem group, all three
clinical failures were aged 65 years or more, had polymicrobial infections, and had
received up to nine doses. Two of the three patients had had previous intra-abdominal
surgery. In the imipenem/cilastatin group, the five clinical failures were aged between 26
and 78 years and had received up to 42 doses; none of these failures had received previous
intra-abdominal surgery. All other patients (17 meropenem, 11 imipenem/ cilastatin) who
had undergone surgery in the two months before the study had satisfactory clinical
responses. All nine patients with septicaemia (three meropenem, six imipenem/cilastatin)
were considered clinically cured at the end of treatment and at follow-up.
Table III. Clinical features of intra-abdominal infections at entry to the study
Peritonitis*
diffuse
local
none
Anatomical site of infection
stomach/duodenum
bilary tract/liver
cholecystitis
cholangitis
pancreas
appendix (complicated)
appendix (uncomplicated)
appendix (unclassified)
small/large bowel
previous surgery
others
Infection severity
mild
moderate
severe
All
Meropenem
(n= 116)
26(4)
60(19)
30(21)
3
5
16
1
22
18
2
22
22
5
21
69
26
patients
Imipenem/
cilastatin
(n= 116)
36(5)
49(14)
31 (22)
6
5
19
1
17
14
5
22
17
10
16
69
31
Evaluable
Meropenem
(n = 82)
19(3)
42(17)
21(18)
1
1
12
1
21
5
2
16
19
4
7
54
21
patients
Imipenem/
cilastatin
(n = 88)
30(6)
35(12)
23(19)
4
2
14
1
16
9
4
19
11
8
7
59
22
•Number in parentheses indicates number of patients who also had abscesses.
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Figure 1. Clinical response at the end of treatment: M, meropenem (n = 82); Q, imipenem/cilastatin (n = 88).
Satisfactory bacteriological response (success or presumed success) at the end of
therapy occurred in 69/82 (84%) meropenem patients and 71/88 (81%) imipenem/
cilastatin patients (Figure 2); the difference (3-46%) was not statistically significant
(P = 0-554, 95% CI -8-0%, 14-9%). Response rates at follow-up were very similar with
bacteriological success or presumed success seen in 52/62 (84%) meropenem patients and
in 55/70 (79%) imipenem/cilastatin patients.
In the meropenem group, unsatisfactory bacteriological responses at the end of therapy
in 5/13 patients were due to new organisms arising during the study (11 new organisms
Table IV. Satisfactory clinical response rate at the end of treatment
Peritonitis
diffuse
local
none
Anatomical site of infection
stomach/duodenum
cholecystistis
cholangilis
pancreas
appendix (complicated)
appendix (uncomplicated)
appendix (unclassified)
small/large bowel
Previous surgery
Other
Total
Meropenem
(n =
n
18/19
40/42
21/21
1/1
1/1
12/12
1/1
21/21
5/5
2/2
15/16
17/19
4/4
79/82
82)
%
95
95
100
96
Imipenem/cilastatin
(n =
n
27/30
34/35
22/23
3/4
2/2
14/14
0/1
16/16
9/9
4/4
16/19
11/11
8/8
83/88
88)
%
90
97
96
94
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Table V. Characteristics of patients whose intra-abdominal infections were clinically unchanged/
worse following study treatment
Previous
Causative organisms identified at entry surgeryPrimary diagnosis
Meropenem
Diffuse peritonitis
(caecum/colon)
Local peritonitis
/cholecystitis
/intra-abdominal abscess
Local peritonitis
/anastomotic
dehiscence
E. coli, Acinetobacter luoffi, Klebsiella pneumo- No
niae, P. aeruginosa. Proteus mirabilis, Entero-
coccusfaecalis, Enierococcus faecium. Clostridium
sp.
Bacteroides merdae, E. coli, K. pneumoniae. Yes
P. mirabilis, Peptococcus sp.. Peptostreptococcus
sp., /?-haemolytic streptococcus, non-haemolytic
streptococcus
E. coli, Klebsiella oxvtoca Yes
Imipenem/cilastatin
Diffuse peritonitis
/perforated small
bowel
Local peritonitis
/intra-abdominal
abscess/diverticulitis
Diffuse peritonitis
/perforated sigmoid
Pancreatic abscess
Diffuse peritonitis
/perforated duodenal ulcer
E. coli No
Clostridium innocuum. Clostridium tyrobutyri- No
cium, E. coli. Eubacterium lentum. Enterococcus
avium
P. aeruginosa1', Candida albicany1 No
E. faecalis' No
Clostridium sporogenes. S. aureus No
•New organism arising during the study.
isolated), compared with 9/17 failures in the imipenem/cilastatin group (24 new organisms
isolated). In the meropenem group, seven of the 11 new organisms were Gram-positive
aerobes, two were Gram-negative aerobes, one was an anaerobe and one was a yeast. In
the imipenem/cilastatin group, of the 24 new organisms cultured, nine were Gram-positive
aerobes, eight were Gram-negative aerobes. six were anaerobes and one was a yeast.
In the 120 patients with polymicrobial intra-abdominal infections (60 meropenem; 60
imipenem/cilastatin) there was a high level (95%) of clinical cure or improvement in both
treatment groups. A satisfactory bacteriological response was achieved in 49/58 (85%)
meropenem patients compared with 46/58 (79%) imipenem/cilastatin patients; this
difference was not statistically significant.
In addition, the bacteriological response for each bacterial species was evaluated.
A similar distribution of Gram-positive aerobic bacteria (30%). Gram-negative aerobes
(39%) and anaerobes (31 %) was found throughout the study population. The percentages
of causative organisms with a satisfactory response are given in Table VI. The commonest
organisms, E. coli and B.fragilis group, were eradicated or presumed eradicated in 44/48
(92%) and 27/28 (96%), respectively, of the meropenem patients and 48/51 (94%) and
20/21 (95%), respectively, of the imipenem/cilastatin group.
200 S. J. Geroulanos & Meropenem Study Group
All new organisms arising during the study were assessed to evaluate the tendency of
the study drug to select out certain bacterial or fungal strains. Superinfections were
defined as those requiring further antimicrobials or surgery, whereas colonisation
required no further therapy. Nineteen meropenem and 24 imipenem/cilastatin patients
had superinfections and/or colonisations at one or more sites. There were fewer
superinfections in the meropenem group compared with the imipenem/cilastatin group
(5/82 vs 12/88), whereas the number of colonisations was similar (16/82 vs 16/88).
In the meropenem group four of the five superinfections were from drain sites and one was
in the blood. One of the patients with a drain site superinfection also had Candida sp.
isolated in the blood. In the imipenem/cilastatin group, four superinfections were from
drain sites, four were from samples taken during further surgery (two of these four
patients also had organisms isolated in the blood), one from abscess needle puncture and
three in the urine. There was no difference in the incidence of fungi/yeasts cultured from
the treatment groups.
Sensitivity testing of the colonising or superinfecting organisms isolated from
intra-abdominal sites against both study drugs revealed ten strains to be resistant to
meropenem and nine to imipenem, the resistant organisms being: enterococci, S. milleri
and a coagulase-negative staphylococcus (presumed methicillin resistant).
Safety
Overall, 72 adverse events were experienced by 45/116 (39%) meropenem patients
and 65 adverse events were experienced by 42/116 (36%) imipenem/cilastatin
patients.
In the meropenem group, 33 patients (28%) experienced adverse events that were
considered to be drug-related, compared to 29 patients (25%) in the imipenem/cilastatin
group. Incidences of adverse events occurring in more than one patient are shown in
Table VII. Most adverse events were mild or moderate in intensity.
100
Successor
presumed success
Partial Failure or Superinfection
success presumed failure
Figure 2. Bacteriological response at the end of treatment: • , meropenem (n = 82); • . imipenem,cilastatin
(n = 88).
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Table VI. Satisfactory response rate of individual organisms
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Gram-positive aerobes
Enterococci
Viridans streptococci
Staphylococcus epidermidis
S. aureus
Staphylococcus spp.
Others
Total
Gram-negative aerobes
E. coli
Klebsiella spp.
P. mirabilis
P. aeruginosa
Morganella morganii
Others
Total
Anaerobes
B. fragilis Group.
Bacteroides spp.
Peptostreptococcus spp.
Clostridium perfringens
Others
Total
Overall total
Meropenem
n
12/18
28/29
5/6
3/3
3/3
18/20
69/79
44/48
10/13
3/5
2/4
3/3
18/19
80/92
27/28
3/3
4/5
3/3
34/37
71/76
220/247
%
67
97
83
100
100
90
87
92
77
60
50
100
95
87
96
100
80
100
92
93
89
Imipenem/cilastatin
n
13/13
15/16
2/4
2/3
1/1
19/21
52/58
48/51
6/6
3/3
6/7
1/2
16/17
80/86
20/21
1/1
2/2
5/5
30/35
58/64
190/208
%
100
94
50
67
100
90
90
94
100
100
86
50
94
93
95
100
100
100
86
91
91
The most frequently reported adverse events in both treatment groups were injection
site inflammation, elevated AST and elevated ALT. Injection site inflammation was
reported in nine meropenem and 13 imipenem/cilastatin patients. The AST was increased
in seven meropenem and six imipenem/cilastatin patients whilst the ALT was increased
in six patients in each group.
Table VII. Adverse events considered drug-related occurring in more than one
patient
Injection site inflammation
AST increased
ALT increased
Prothrombin time increased
Alkaline phosphatase increased
Lactic dehydrogenase increased
Eosinophilia
Nausea
Diarrhoea
Vomiting*
Meropenem
( n = 116)
9
7
6
4
4
3
2
2
2
1
Imipenem/cilastatin
(n= 116)
13
6
6
1
3
—
3
1
1
2
•One patient from each group experienced nausea and vomiting
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Five patients (one meropenem and four imipenem/cilastatin) were withdrawn due to
adverse events which were considered drug-related: severe nausea (meropenem), severe
nausea and vomiting (imipenem/cilastatin), injection site inflammation (two imipenem/
cilastatin patients) and severe hypotension (imipenem/cilastatin).
There were nine deaths during the study period, six in the meropenem group and three
in the imipenem/cilastatin group. In two cases (meropenem group), the possibility of a
relationship to treatment was not excluded by the investigator. Both patients were elderly
and died of complications of their underlying disease subsequent to septic shock, one of
cardiac failure and one of hepatic failure. The patient who died of hepatic failure had
abnormal liver function tests at study entry.
Although a high proportion of renally-impaired patients inadvertently received higher
doses than those recommended, there were no safety problems in these patients.
There were no gross differences between treatment groups for haematological
variables, with the exception of prothrombin time which was increased in a greater
number of meropenem patients. However, none of these changes was considered to be
drug-related, and the changes were transient, or clearly related to other factors (e.g.
warfarin administration).
Following review of all haematological/biochemical variables, meropenem produced
no clinically significant abnormalities in blood elements, clotting systems, renal func-
tion or hepatic biochemistry. When elevations in transaminases more than three times
greater than baseline values were reviewed, there were no differences between treatments.
Overall, the changes seen in haematology and biochemistry with meropenem compared
favourably with those seen with imipenem/cilastatin.
The safety profiles of meropenem and imipenem/cilastatin were similar and none of
the differences was considered to be clinically significant.
Discussion
Whilst surgery is usually required for the treatment of intra-abdominal infections,
safe and effective broad spectrum antibiotics are needed for immediate empirical
treatment of patients presenting with such infections. The results of this large,
international study indicate that the clinical and bacteriological efficacy of meropenem
and imipenem/cilastatin were equivalent, with high success rates seen in both groups at
treatment end and at follow-up.
These results compare well with other studies in intra-abdominal infections. A review
of worldwide clinical experience with imipenem/cilastatin has shown an overall clinical
efficacy rate of 91 % (Clissold, Todd & Campoli-Richards, 1987), whilst individual studies
have shown satisfactory clinical response rates of 69% (Eklund ei al., 1993), 96%
(Eckhauser et al., 1992) and 86% (Norwegian Study Group, 1987), in comparison with
piperacillin plus tazobactam (93%), clindamycin plus gentamicin or tobramycin (92%)
and cefotaxime plus metronidazole and cloxacillin (92%), respectively.
Imipenem/cilastatin is a recognised standard treatment for intra-abdominal infections
and has been shown to be as effective as combination treatment (Geddes & Roylance,
1991). In the present study, meropenem and imipenem/cilastatin showed a broad
spectrum of activity against Gram-positive and Gram-negative aerobes, and anaerobes.
In particular, both meropenem and imipenem/cilastatin were highly effective against
E. coli (the commonest causative organism), B. fragilis group and Streptococcus spp.
The small numbers of patients with other causative organisms do not allow for meaningful
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comparisons. Meropenem and imipenem/cilastatin produced high clinical response rates
irrespective of the pathology of infection, i.e. whether the peritonitis was local or diffuse,
or whether an abscess was present.
Although the number of colonisations was similar in both treatment groups, there were
fewer superinfections in patients receiving meropenem. Superinfections contribute to
treatment failure and their prevention is therefore beneficial. Of the resistant strains of
new organisms which were isolated from intra-abdominal cultures, Enterococcusfaecium
and methicillin-resistant staphylococci have documented resistance to carbapenems
(Benfield & Chrisp, 1992; Havlik, 1993).
Whilst the tolerability of imipenem/cilastatin is acceptable, this combination product
is not without problems; seizures have been reported in patients receiving imipenem/
cilastatin (Calandra et al., 1988a). In this study, no seizures were reported. However,
patients with known CNS abnormalities were excluded. Animal data have shown that
meropenem has a lower seizure potential than imipenem/cilastatin; whereas both
imipenem and imipenem/cilastatin produced significant potentiation of metrazole-
induced seizures in mice, no significant potentiation was seen with meropenem (Patel &
Giles, 1989; Hori, Kanemitsu & Shimada, 1992). Clinical support for these results was
seen in a meningitis study in which there were no drug-related seizures in patients receiving
either meropenem or a cephalosporin (Lopez et al., 1993).
Imipenem/cilastatin has also been associated with nausea and/or vomiting especially
when given by rapid infusion; vomiting is particularly hazardous in surgical patients as
it can lead to wound breakdown. However, the design of this study removed any
possibility of showing between-group differences, since imipenem/cilastatin was
administered by slow infusion because of this previous experience with the drug. There
is no evidence of a relationship between rate of infusion/dose and incidence of nausea
and/or vomiting for meropenem.
The most common adverse reactions reported were injection site inflammation and
elevated transaminases, which occurred to a similar extent in both groups. Pain at
injection site tends to occur with /Mactam antibacterials, as does phlebitis,
thrombophlebitis and venous pain (Buckley et al., 1992). In this study, inflammation at
the injection site occurred to a similar extent in both groups. However, it led to withdrawal
in two imipenem/cilastatin patients.
Transient increases in AST and ALT levels have been previously reported in
imipenem/cilastatin studies, although it is difficult to know whether these are due to the
drug or the underlying infection treated, and few were considered to be drug-related
(Wange/fl/., 1985; Wise, 1990; Buckley et al., 1992). When liver function test results from
the present study were reviewed for changes or trends, meropenem compared favourably
with imipenem/cilastatin. A careful review of renal function tests revealed no evidence
of nephrotoxicity with meropenem and there was no identifiable increase in adverse events
in renally-impaired patients.
In this study, meropenem was as well tolerated as imipenem/cilastatin. It should also be
borne in mind that this was an open study and the likelihood is much higher of minor
adverse events being reported for a new treatment (meropenem) as opposed to an
established regimen (imipenem/cilastatin). Furthermore, the study was designed to reduce
the known intolerance of imipenem/cilastatin which results from rapid infusion.
In conclusion, meropenem (1 g every 8 h) is highly effective in the treatment
of intra-abdominal sepsis, producing a high rate of clinical and bacteriological
response. It has equivalent efficacy to imipenem/cilastatin and has a particularly high
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efficacy against anaerobes. Meropenem and imipenem/cilastatin also showed equivalent
tolerability in this study. Meropenem offers greater flexibility of administration than
imipenem/cilastatin and can confidently be given as empirical monotherapy by
intravenous infusion or bolus injection for the treatment of moderate to severe
intra-abdominal infections.
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